Life sciences and diagnostics company Danaher (NYSE: DHR) is likely to have a great year, but what about 2022 and beyond? That's the key question that investors will be asking themselves after yet another excellent earnings report from the company. Let's take a look at the earnings and guidance in assessing the investment case for the company.
With full-year headline revenue up 24.5% and core revenue (including the Cytiva biopharma business bought from General Electric) up 9.5%, Danaher had another super year. Revenue growth was driven by the Cytiva acquisition (life sciences) and by a boost in demand from the COVID-19 pandemic. Danaher's life sciences segment was a beneficiary of spending on developing vaccines and therapies for COVID-19. Meanwhile, the diagnostics segment benefited from demand for its COVID-19 tests and associated flu tests.
Image source: Getty Images.
Source Fool.com